Aldeyra Therapeutics

Aldeyra's roller coaster month ends with 'positive' phase 2 chronic cough readout
Aldeyra's roller coaster month ends with 'positive' phase 2 chronic cough readout
Fierce Biotech
Aldeyra Therapeutics
clinical trials
ADX‑629
chronic cough
Flag link:
Aldeyra Therapeutics reports that FDA rejects eye cancer drug
Aldeyra Therapeutics reports that FDA rejects eye cancer drug
Benzinga
Aldeyra Therapeutics
FDA
eye cancer
ADX-2191
Flag link:
Go or no go? Key FDA decisions for Argenx and Regeneron
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Flag link:
Major readouts on the horizon for small developers
Major readouts on the horizon for small developers
EP Vantage
Aldeyra Therapeutics
Autolus Therapeutics
Bavarian Nordic
BioXcel Therapeutics
Disc Medicine
Editas Medicine
Immunogen
Lantheus
Mersana Therapeutics
NGM Biopharmaceuticals
Omeros
Roche
Sutro BioPharma
uniQure
Valneva
Viking Therapeutics
Flag link:
Aldeyra reports positive data from dry eye disease therapy trial
Aldeyra reports positive data from dry eye disease therapy trial
Clinical Trials Arena
Aldeyra Therapeutics
clinical trials
reproxalap
dry eye disease
Flag link:
Aldeyra’s sights set on November PDUFA
Aldeyra’s sights set on November PDUFA
Endpoints
Aldeyra Therapeutics
dry eye disease
reproxalap
FDA
Flag link:
Aldeyra says eye drop clears three dry eye signals en route to FDA
Aldeyra says eye drop clears three dry eye signals en route to FDA
Endpoints
Aldeyra Therapeutics
dry eye disease
FDA
clinical trials
reproxalap
Flag link:
Aldeyra Prepares to Submit Dry Eye Disease Treatment Reproxalap to FDA
Aldeyra Prepares to Submit Dry Eye Disease Treatment Reproxalap to FDA
BioSpace
Aldeyra Therapeutics
dry eye disease
reproxalap
clinical trials
Flag link:
Aldeyra builds case for troubled dry eye drug reproxalap
Aldeyra builds case for troubled dry eye drug reproxalap
Pharmaforum
Aldeyra Therapeutics
dry eye disease
reproxalap
Flag link:
Watch out Claritin: Aldeyra announces clean sweep in PhIII for new allergy drug
Watch out Claritin: Aldeyra announces clean sweep in PhIII for new allergy drug
Endpoints
Aldeyra Therapeutics
clinical trials
allergies
reproxalap
ragweed pollen allergy
Flag link:
3 Biotech Stocks That Jumped Last Week
3 Biotech Stocks That Jumped Last Week
Motley Fool
biotech
biotech stocks
Lexicon Pharmaceuticals
sotagliflozin
Nucana
Aldeyra Therapeutics
reproxalap
Flag link:
The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings
The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings
Yahoo/Benzinga
JNJ
Flexion Therapeutics
Novartis
Amgen
Clearside Biomedical
Alexion
Assertio Therapeutics
Aldeyra Therapeutics
Lineage Therapeutics
IMMUTEP
Marinus Pharma
Flag link:
Aldeyra's Reproxalap Falls Short in Anterior Uveitis Trial
Aldeyra's Reproxalap Falls Short in Anterior Uveitis Trial
BioSpace
Aldeyra Therapeutics
reproxalap
non-infectious anterior uveitis
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Regeneron
Sanofi
Praluent
FDA
Heron Therapeutics
HTX-011
Nabiva
Orchard Therapeutics
Akari Therapeutics
Aldeyra Therapeutics
BioTime
Audentes Therapeutics
Adaptimmune
GW Pharma
Ionis
Biogen
Ovid Therapeutics
TransMedics
IPOs
Trevi Therapeutics
Flag link:
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
Xconomy
Aldeyra Therapeutics
clinical trials
FDA
eye health
reproxalap
seasonal allergic conjunctivitis
Flag link:
Aldeyra plans reproxalap phase 3 after wrapping up dry eye disease trial
Aldeyra plans reproxalap phase 3 after wrapping up dry eye disease trial
Fierce Biotech
Aldeyra Therapeutics
dry eye disease
clinical trials
reproxalap
Flag link:
J&J collaborates with Aldeyra on new drugs for systemic inflammatory diseases
J&J collaborates with Aldeyra on new drugs for systemic inflammatory diseases
Endpoints
JNJ
Aldeyra Therapeutics
inflammatory disease
R&D
Flag link:
Aldeyra slides as lead drug flunks a primary endpoint in PhIIb
Aldeyra slides as lead drug flunks a primary endpoint in PhIIb
Endpoints
Aldeyra Therapeutics
clinical trials
ADX-102
allergic conjunctivitis
Flag link:
IPO Preview: Aldeyra Therapeutics
IPO Preview: Aldeyra Therapeutics
Seeking Alpha
IPOs
Aldeyra Therapeutics
Flag link:
Eager biotechs eye $133M in IPOs as a frenzied quarter closes
Eager biotechs eye $133M in IPOs as a frenzied quarter closes
Fierce Biotech
IPOs
biotech
Aldeyra Therapeutics
GlobeImmune
Agile Therapeutics
Flag link: